Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Esomeprazole 20 mg vs Nexium 24HR in Healthy Adults
NCT05265247Phase 1Completed
- Sponsor
- Haleon
- Start
- Mar 2022
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of esomeprazole in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Haleon. Primary endpoints: Maximum Observed Post Dose Concentration at 24 hours and Area Under the Plasma Concentration Versus Time Curve From Time 0 to Last Measurable Sampling Time Point at 24 hours. Started Mar 2022; status: completed.
02
Drugs
esomeprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05265247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05265247.